HOUSTON and LOUISVILLE, Ky., Oct. 24, 2018 /PRNewswire/ -- NX Prenatal Inc., a privately held women's healthcare molecular diagnostic company, announced today that it has entered into a collaboration with Indiana University School of Medicine to further validate its early pregnancy biomarker panels that predict Spontaneous Preterm Birth (SPTB) and to further develop its biomarker panels for Preeclampsia (PE). "The collaboration builds upon published data in which NX Prenatal has demonstrated that the enrichment of exosome and microvesicle particles from maternal blood and subsequent biomarker analysis enables risk stratification of preterm birth and preeclampsia as early as 10-12 weeks into the pregnancy. This 'early detection' result has not been realized by other approaches," commented Dr. Kevin Rosenblatt, Chief Medical and Scientific Officer of NX Prenatal.
Blood samples from more than 2,300 women will be evaluated at first trimester and second trimester time points. The samples were prospectively collected at more than 20 hospitals affiliated with 8 clinical research centers across the US, including IU School of Medicine. Extensive medical data, demographic data, outcomes, and follow-up data were collected according to standardized protocols. All of the women in the study are "nulliparous," meaning they had not previously given birth, so there was no history of a preterm birth. As such, this is a low-risk population that is the most difficult for physicians to risk-stratify and manage. The size of the study will allow for the evaluation of co-risk factors like age, body mass index, nutrition and socio-economic factors.